Clinical Trial Update: GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prophylaxis in unrelated donor …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Graft-versus-host Disease
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Anti-thymocyte globulin (ATG) (anti-thymocyte globulin)
• Post-transplant cyclophosphamide (PTCy) (cyclophosphamide)

Snippet

Sponsor: DKMS gemeinnützige GmbH | Conditions: Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation | Phase 3 | Status: ACTIVE_NOT_RECRUITING